Oncothyreon Inc's Value Inflection Point -08/27/09 at 9:28 AM CDTby Jaehyung Yoon

Assigning a value to a development-stage biotech company is a questionable task, and generally requires more intangible assumptions (market potential, clinical trial progress, partnership implication) than tangible assumptions (balance sheet, income statement, various financial strength indicators).  However, the merit in such an assessment is that b...